Search Results
123 Results Found for “GLP-1 receptor agonists”
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
Topline data from the TRIUMPH-2 and TRIUMPH-3 trials show substantial weight loss, improved glycemic control, and favorable changes in cardiometabolic risk markers with the investigational triple hormone receptor agonist in adults with obesity and type 2 diabetes or established cardiovascular disease.
Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...
Data presented at ENDO 2026 highlighted investigational approaches for difficult-to-control type 2 diabetes and acquired hypothalamic obesity, real-world outcomes with tirzepatide, and wider health impacts of GLP-1-based therapy.
Dr Eric Ravussin discusses REDEFINE 1 findings from ECO 2026, highlighting improvements in physical function and preserved functional strength despite substantial weight loss with the GLP-1/amylin agonist combination CagriSema.
Dr Laurence Dobbie discusses a new European consensus statement highlighting the nutritional, functional and psychological considerations needed to support safe, effective and equitable use of incretin-based therapies in obesity management.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1RA-based therapies are currently considered to be one of the most attractive classes of medications for managing type 2 diabetes (T2D) because of their impressive weight loss properties, glycated haemoglobin (HbA1c) ...
New data presented at the Advanced Technologies & Treatments for Diabetes 2026 highlight a shift in diabetes care beyond glucose control alone. Emerging evidence supports the growing role of incretin-based therapies such as semaglutide, alongside advances in continuous glucose monitoring systems including Dexcom G7 and Freestyle Libre 3. Together, these innovations demonstrate meaningful improvements in glycemic outcomes, cardiometabolic risk, and patient behaviors, signaling a move toward more personalized, integrated approaches to diabetes management across both type 1 and type 2 diabetes.
Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...
In this roundup, members of the touchNDOCRINOLOGY Expert Faculty share their perspectives on the advances that shaped research and practice over the past year, highlighting a discipline in transition and looking ahead to the opportunities of 2026.
GLP-1 receptor agonists have been a standout development this year, reshaping the treatment of type 2 diabetes and obesity. In this expert perspective, Glenn D Braunstein highlights their expanding benefits, from weight loss and cardiometabolic protection to emerging dual- and tri-agonist therapies, while also addressing key challenges as these agents move rapidly into mainstream clinical practice.
In this interview, Dr Iulia Pirga reflects on key advances in endocrinology, persistent challenges in metabolic disease and the growing potential of AI to transform patient care and clinical decision-making.
Post-bariatric weight regain is a major clinical challenge. In the BARI-STEP trial, semaglutide 2.4 mg weekly led to substantial, sustained weight loss and improved cardiometabolic health. Dr Janine Makarondis discusses the findings and the potential of GLP-1 therapy in this patient population.
Dr Sourabh Sharma, a nephrologist and transplant physician at Safdarjung Hospital and Vardhaman Mahaveer Medical College in New Delhi, shares his thoughts on this year’s key advances, the challenges that remain, and the growing impact of AI on nephrology.
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular-kidney-metabolic health.
Dr John Doupis shares his highlights from EASD 2025, discussing breakthrough trials in diabetes and obesity, emerging therapies, and how advancing technology and AI are reshaping the future of diabetes care.
Fatty liver is the largest liver disease globally and has become a leading cause of liver cirrhosis and end-stage liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic steatohepatitis (NASH), affects about one-third of the adult population ...
TouchENDOCRINOLOGY coverage from EASD 2025: At the EASD 2025 congress (Vienna, Austria; 15–19 September), new research from the University of Sheffield explored the potential role of tirzepatide as an adjunctive therapy in people with type 1 diabetes and obesity. Tirzepatide, a dual GIP and ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
